RW Baird | GenomeWeb

RW Baird

NEW YORK (GenomeWeb News) – RW Baird today downgraded Complete Genomics to Neutral from Outperform on Illumina's introduction of its rapid Individual Genome Sequencing service with a turnaround time of as little as two weeks.

This article has been updated to include comments from Affymetrix.
The strong demand Illumina has seen for its family of exome arrays apparently took the company by surprise, an Illumina executive said last week.

In a research note, analyst Quintin Lai noted the recent FDA approval of the protein biomarker-based test developer's Galectin-3 test, as well as partnerships forged with several IVD instrument manufacturers that could speed adoption of the test.

According to CEO Amit Kumar, talks with "potential suitors" for strategic deals that may include the sale of the company or its businesses are "progressing" and the firm is ready to evaluate offers from interested parties.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.